Compounds and methods for the treatment of dermal and ocular disorders

The compound of any one of the preceding claims, wherein the H1 antagonist is an ethylenediamine (H1 antagonist), ethanolamine (H1 antagonist), alkylamine (H1 antagonist), piperazine (H1 antagonist), tricyclic (H1 antagonist), or tetracyclic (H1 antagonist).

The compound of any one of the preceding claims, wherein the H1 antagonist is a piperazine (H1 antagonist) or a tricyclic (H1 antagonist).

The compound of any one of the preceding claims, wherein the H1 antagonist comprises two aromatic rings (e.g., connected to a (central) carbon, nitrogen, or CO).

The compound of any one of the preceding claims, wherein the H1 antagonist comprises an amine (e.g., amine substituted with alkyl, such as methyl).

The compound of any one of the preceding claims, wherein the H1 antagonist comprises a spacer (e.g., between the amine and the (central) carbon, nitrogen, or CO).

The compound of any one of the preceding claims, wherein the H1 antagonist is selected from the group consisting of olopatadine, cetirizine, acrivastine, bilastine, fexofenadine, levocabastine, hydroxyzine, periciazine, and quetiapine.

The compound of any one of the preceding claims, wherein the H1 antagonist is selected from the group consisting of olopatadine, cetirizine, acrivastine, bilastine, fexofenadine, and levocabastine.

The compound of any one of the preceding claims, wherein the H1 antagonist is olopatadine or cetirizine.

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein each linker (e.g., L or LA) is independently a bond, substituted or unsubstituted (e.g., branched or straight) alkyl (alkylenyl), or substituted or unsubstituted (e.g., branched or straight) heteroalkyl (heteroalkylenyl).

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein each linker (e.g., L or LA) is independently a bond or substituted or unsubstituted (e.g., branched or straight) alkyl (alkylenyl) (e.g., >C(═O)).

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the linker (e.g., L or LA) is a bond.

A compound having the structure:

• or a pharmaceutically acceptable salt or solvate thereof.

A compound having the structure:

• or a pharmaceutically acceptable salt or solvate thereof.

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the linker is a non-hydrolyzable linker.

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the compound (e.g., the linker of the compound) is enzymatically stable.

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the compound (e.g., the linker of the compound) is not cleavable by enzymes, such as enzymes of the skin and/or eye (e.g., esterases, hydrolases, or reductases).

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the compound (e.g., the linker of the compound) is stable in an aqueous environment, such as a biological environment and/or a buffered solution).

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the compound has anti-parasitic activity.

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the compound has keratolytic activity.

The topical pharmaceutical composition or compound of any one of the preceding claims, wherein the compound has antihistamine activity.

A pharmaceutical composition comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

A method of treating a dermal or an ocular disease or disorder in an individual, comprising administering to the individual a compound or composition of any one of the preceding claims.